[go: up one dir, main page]

WO1999036030A3 - Pharmaceutical composition and method for treating di-hydroxytestosterone dependent conditions - Google Patents

Pharmaceutical composition and method for treating di-hydroxytestosterone dependent conditions Download PDF

Info

Publication number
WO1999036030A3
WO1999036030A3 PCT/US1999/001207 US9901207W WO9936030A3 WO 1999036030 A3 WO1999036030 A3 WO 1999036030A3 US 9901207 W US9901207 W US 9901207W WO 9936030 A3 WO9936030 A3 WO 9936030A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating
androgenic
dependent conditions
binds
dosage form
Prior art date
Application number
PCT/US1999/001207
Other languages
French (fr)
Other versions
WO1999036030A2 (en
Inventor
Daniel Foitl
Original Assignee
Davitz Michael A
Leason David
Daniel Foitl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Davitz Michael A, Leason David, Daniel Foitl filed Critical Davitz Michael A
Priority to AU24619/99A priority Critical patent/AU2461999A/en
Publication of WO1999036030A2 publication Critical patent/WO1999036030A2/en
Publication of WO1999036030A3 publication Critical patent/WO1999036030A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A pharmaceutical composition for treating DHT dependent conditions including androgenic alopecia is disclosed. An oral dosage form according to the invention includes a therapeutically effective amount of a 5α-Reductase inhibitor and another active compound which binds with androgenic receptors. In a preferred form, the bio-available concentration of the compound which binds with androgenic receptors is limited or controlled to avoid appreciable anti-androgenic side effects, for example, by providing a controlled (timed or sustained release) coating on that active compound. Spironolactone is a particularly preferred compound which binds with androgenic receptors. A preferred dosage form has the ratio of the 5α-Reductase inhibitor to spironolactone in the range of 1:5 to 1:2500. A method for creating an oral dosage form for treating DHT dependent conditions is also disclosed.
PCT/US1999/001207 1998-01-16 1999-01-19 Pharmaceutical composition and method for treating di-hydroxytestosterone dependent conditions WO1999036030A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU24619/99A AU2461999A (en) 1998-01-16 1999-01-19 Pharmaceutical composition and method for treating di-hydroxytestosterone dependent conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US796498A 1998-01-16 1998-01-16
US09/007,964 1998-01-16

Publications (2)

Publication Number Publication Date
WO1999036030A2 WO1999036030A2 (en) 1999-07-22
WO1999036030A3 true WO1999036030A3 (en) 1999-09-23

Family

ID=21729079

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/001207 WO1999036030A2 (en) 1998-01-16 1999-01-19 Pharmaceutical composition and method for treating di-hydroxytestosterone dependent conditions

Country Status (2)

Country Link
AU (1) AU2461999A (en)
WO (1) WO1999036030A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0213745D0 (en) * 2002-06-14 2002-07-24 Univ Edinburgh Enzyme
US7790706B2 (en) 2002-06-14 2010-09-07 The University Of Edinburgh Treatment of inflammation with 5α reduced metabolites
DE10303509A1 (en) * 2002-08-23 2004-03-04 Koc, Felix, Dr. Hair growth promoting composition contains finasteride for oral administration in combination with biotin or for external administration
RU2316328C1 (en) * 2006-05-30 2008-02-10 Государственное образовательное учреждение дополнительного профессионального образования Санкт-Петербургская медицинская академия последипломного образования Федерального агентства по здравоохранению и социальному развитию Method for correction of partial age androgen deficiency (padam) and preparative formulation of testosterone or its pharmacologically acceptable derivatives for its realization
WO2011014649A1 (en) 2009-07-29 2011-02-03 Duke University Compositions and methods for inhibiting hair growth

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017168A1 (en) * 1993-12-21 1995-06-29 Applied Analytical Industries, Inc. Method for preparing low dose pharmaceutical products

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017168A1 (en) * 1993-12-21 1995-06-29 Applied Analytical Industries, Inc. Method for preparing low dose pharmaceutical products

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ERENUS M., ET AL.: "COMPARISON OF FINASTERIDE VERSUS SPIRONOLACTONE IN THE TREATMENT OFIDIOPATHIC HIRSUTISM.", FERTILITY AND STERILITY., ELSEVIER SCIENCE INC, NEW YORK, NY, USA, vol. 68., no. 06., 1 December 1997 (1997-12-01), USA, pages 1000 - 1003., XP002920808, ISSN: 0015-0282, DOI: 10.1016/S0015-0282(97)00371-3 *
KNOCHENHAUER E. S., AZZIZ R.: "ADVANCES IN THE DIAGNOSIS AND TREATMENT OF THE HIRSUTE PATIENT.", CURRENT OPINION IN OBSTETRICS AND GYNECOLOGY., RAPID SCIENCE PUBLISHERS., US, vol. 07., no. 05., 1 October 1995 (1995-10-01), US, pages 344 - 350., XP000618511, ISSN: 1040-872X *
SHAW J. C.: "ANTIANDROGEN THERAPY IN DERMATOLOGY.", INTERNATIONAL JOURNAL OF DERMATOLOGY, WILEY-BLACKWELL PUBLISHING LTD., UK, vol. 35., no. 11., 1 November 1996 (1996-11-01), UK, pages 770 - 778., XP002920809, ISSN: 0011-9059, DOI: 10.1111/j.1365-4362.1996.tb02970.x *

Also Published As

Publication number Publication date
AU2461999A (en) 1999-08-02
WO1999036030A2 (en) 1999-07-22

Similar Documents

Publication Publication Date Title
FI973828L (en) Compounds and compositions for delivering active ingredients
CA2370565A1 (en) Dermally applicable vitamin d-containing pharmaceutical compositions
AU5699399A (en) Pyridyl-bridgehead derivatives and their analogues, pharmaceutical compositions and their use as inhibitors of nicotinic cholinergic receptors
MXPA03011494A (en) Composition and method for improving plant growth.
HUP9900457A3 (en) Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
AU2681299A (en) Aqueous coating compositions, coated substrate and method related thereto
AU8779898A (en) Compositions and treatments to reduce side effects of administration of androgenic testosterone precursors
MY133564A (en) Compositions and methods for treating osteoporosis and lowering cholesterol
EP1495754A3 (en) Method and composition for treating cancers
CA2366702A1 (en) Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
EP0821587A4 (en) Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs
WO2000003749A3 (en) Method for regulating hair growth
AP1745A (en) Pharmaceutical compositions of amlodipine and atorvastatin.
NO982006L (en) Therapeutic preparation for transdermal delivery of active substances through the skin
AU6202299A (en) Compositions for the treatment and prevention of neurological and pathopsychological diseases
WO2001030802A3 (en) Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
BG103000A (en) Compositions for single daily dosage in the treatment of cyclooxygenase-2-dependent diseases
WO1999063976A3 (en) Liver-selective glucocorticoid antagonist for treating diabetes
IL139861A0 (en) 17β-AMINO-AND HYDROXYLAMINO -11 β-ARYLSTEROID DERIVATIVES, METHODS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
WO1999036030A3 (en) Pharmaceutical composition and method for treating di-hydroxytestosterone dependent conditions
NO20045385L (en) Pharmaceutical preparation containing oxcarbazepine with controlled release of active substance
CA2320878A1 (en) Morphine sulphate microgranules, method for making same and pharmaceutical preparations
IL142598A0 (en) Preparations for topical application of substances having antiandrogenic effect
EP1340502A3 (en) Androstane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
CA2214601A1 (en) Mercapto and seleno derivatives as inhibitors of nitric oxide synthase

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
WA Withdrawal of international application